Compare Gilead Sciences, Inc. (GILD) vs Lennar Corporation (LEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Lennar Corporation — how do they compare? Gilead Sciences, Inc. trades at $133.26 (market cap $163.51B), while Lennar Corporation trades at $86.53 (market cap $20.49B). The key difference: Gilead Sciences, Inc. is far larger — about 8× Lennar Corporation's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | LEN | |
|---|---|---|
Market Cap | $163.51B | $20.49B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $142.40 |
52-Week Low | $108.22 | $82.30 |
Enterprise Value | $178.05B | $24.37B |
Dividend Yield | 2.49% | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Lennar (LEN) trades at $83.71, showing modest daily gains but facing significant technical headwinds with a bearish moving average signal and recent earnings misses. The stock appears fundamentally undervalued with a P/E of 13.37 and P/B of 0.95, though profitability metrics have compressed with net income margin declining to 4.93% in 2025. Recent corporate actions include consistent $0.50 quarterly dividends, while news highlights the company's strategic shift toward volume over price amid housing affordability challenges.
The outlook presents a value opportunity with attractive valuation multiples, but execution risks remain high as Lennar navigates margin pressure from lower home prices and elevated mortgage rates. Analyst consensus leans bullish with a $84.78 price target, though recent earnings disappointments and bearish technical indicators suggest near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
